RxDoctor Payments Data

Mary Polk, MD

Pulmonary Disease · Springfield, ILNPI 1427158104

Payments from drug & device makers

$10,565in general payments, 2019–2025

Across 457 payments — averaging $23.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$1K
  • Inspire Medical Systems, Inc.$1K
  • Regeneron Healthcare Solutions, Inc.$640
  • Actelion Pharmaceuticals US, Inc.$550
  • Grifols USA, LLC$533
  • plus $5K from 37 others

What the payments were for

  • Travel & lodging$9149%
  • Food & beverage$9,61791%
  • Education$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,565 in reported general payments places this provider in the 75th percentile of 539 pulmonary disease providers in Illinois.

See all pulmonary disease providers in Illinois

Medicare billing

Part B allowed, 2024
$105,999
Medicare patients
439
Services billed
1,502

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate44$540,917
Trelegy ElliptaFluticasone/Umeclidin/Vilanter458$336,262
Breztri AerosphereBudesonide/Glycopyr/Formoterol266$205,322
Fasenra PenBenralizumab17$102,066
Breo ElliptaFluticasone/Vilanterol137$63,255
Pirfenidone13$45,591
Dupixent PenDupilumab12$44,726
Stiolto RespimatTiotropium Br/Olodaterol Hcl59$40,251
Spiriva RespimatTiotropium Bromide54$31,212
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr51$30,252
SymbicortBudesonide/Formoterol Fumarate94$25,119
Albuterol Sulfate HfaAlbuterol Sulfate528$12,936
Incruse ElliptaUmeclidinium Bromide34$11,713
Roflumilast127$10,624
Varenicline Tartrate36$9,648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$469$612,380157 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$1,251$450,212716 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,454$230,441360 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 539 pulmonary disease providers in Illinois.

Other pulmonary disease in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →